Table 1.
Study characteristics and quality.
| First author, year, country |
Sample size (E/C) |
Age (F) |
TNM | Intervention (E/C) |
Treatment course (C/W/D) |
KPS | Jadad score |
|---|---|---|---|---|---|---|---|
| Xie, 2014, [22] China |
45/45 | 35~68 | — | SFI + CAF | 4~6 C, 3 W/C |
— | 4 |
| Liang, 2014, [23] China |
27/27 | 29~57 | III-IV | SFI + CTF | 2 C, 21 D/C | ≥60 | 3 |
| Zhang, 2013, [24] China | 32/32 | 32–67 | — | SFI + GEM, CDDP | 21 D | ≥60 | 4 |
| Kawuli, 2011, [25] China | 40/40 | 28~65 | III-IV | SFI + TPX, E-ADM |
3 C, 3 W/C, 7 D/W |
≥60 | 3 |
| Xu, 2010, [26] China |
28/24 | 47/49 | — | SFI + TA | 4 C, 21 D/C | ≥60 | 3 |
| Huang, 2008, [27] China |
30/30 | 47/46 | III-IV | SFI + CTF | 2 C, 21 D/C | ≥60 | 4 |
| Yuan, 2008, [28] China |
38/35 | 19~60 | II-III | SFI + CAF | 20 D | >60 | 3 |
| Zhu, 2008, [29] China |
32/24 | 52.5/51 | I–III | SFI + CEF | 10 D | — | 4 |
| Qiu, 2010, [30] China |
24/23 | 52.04/52.17 | III-IV | SFI + TPX, E-ADM |
2 C, 3 W/C | ≥60 | 3 |
| Dai, 2007, [31] China |
65/61 | 26~70 | II-III | SFI + CEF | 2 C, 28 D/C | >80 | 3 |
| Chen, 2007, [32] China |
34/34 | 38~64 | I-II | SFI + CEF | 6 C, 21 D/C | — | 3 |
| Wang, 2006, [33] China |
40/32 | 45.2 ± 9.8/46.7 ± 0.5 | — | SFI + 5-FU, E-ADM, CTX |
6 C, 21 D/C | ≥60 | 3 |
| Xiao, 2005, [34] China |
55/53 | 43~63 | — | SFI + FEC | 8 D | ≥60 | 3 |
| Li, 2004, [35] China |
40/35 | 56.4/54.2 | IV | SFI + NE | 3 C, 28 D/C | ≥80 | 3 |
| Cui, 2011, [36] China |
22/20 | 33~62 | — | SFI + FAC, AC | 4–6 C, 5–8 D/C |
>80 | 3 |
| Li, 2002, [37] China |
35/27 | 47.2 ± 10.8/46.7 ± 10.5 | — | SFI + 5-FU, CTX, MMC |
3 C, 21 D/C | >50 | 3 |
| Song, 2004, [38] China | 21/25 | 52/58 | II-III | SFI + CMF | 2 C, 2 W/C | — | 3 |
| Wu, 2012, [39] China |
36/36 | 35~69 | — | SFI + CMF | 4 C, 28 D/C | — | 3 |
Note: E/C: experimental group/control group; F: female; TNM: T: tumor, N: lymph node, and M: metastasis; C: cycle; W: week; D: day; KPS: Karnofsky; SFI: shenqi fuzheng injection; CAF: CTX (cyclophosphamide) and ADM (Adriamycin) and 5-FU (5-fluorouracil); CTF: CTX and THP (Therarubicin) and 5-FU; TA: PTX (Paclitaxel) and E-ADM/EPI (epirubicin); CEF: CTX and E-ADM/EPI and 5-FU; TE: PTX and EPI; FEC: CTX and 5-FU and EPI; NE: NVB (Vinorelbine) and E-ADM; FAC: 5-FU and ADM and CTX; AC: ADM and CTX; CMF: CTX and MTX (Methotrexate) and 5-FU; CDDP: cisplatin; MMC: mitomycin; GEM: gemcitabine; Jadad score: modified Jadad scale that was used.